MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024
2024-09-02
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER FOLLOWING ENDOCRINE TREATMENT TO BE PRESENTED AT 2024 CSCO
2024-08-29
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
2024-08-28
VOLUNTARY ANNOUNCEMENT - THREE RESEARCH RESULTS OF "TQC3721 (PDE3/4 INHIBITOR)" AND "TQC2731 (TSLP MONOCLONAL ANTIBODY)" WILL BE PRESENTED AT ERS 2024
2024-08-26
INTERIM DIVIDEND FOR 2024
2024-08-13
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
2024-08-13
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARINOMA
2024-08-01
NOTIFICATION OF BOARD MEETING
2024-07-31
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024
2024-07-31
VOLUNTARY ANNOUNCEMENT - ESG PERFORMANCE RECOGNISED BY S&P GLOBAL AND FTSE RUSSELL
2024-07-19
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG CULMERCICLIB CAPSULE "CULMERCICLIB (TQB3616)"
2024-07-18
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA
2024-07-16
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG ROVADICITINIB TABLET "ROVADICITINIB (TQ05105)"
2024-07-15
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024
2024-07-02
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "LIRAGLUTIDE INJECTION"
2024-06-25
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME
2024-06-20
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ISSUANCE OF FIRST TRANCHE OF PANDA BONDS
2024-06-20
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNOVATIVE DRUG ENVONALKIB CITRATE CAPSULES "ENVONALKIB (TQ-B3139)"
2024-06-19
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME
2024-06-13
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "GADOTERIDOL INJECTION"
2024-06-12
VOLUNTARY ANNOUNCEMENT - PUBLICATION OF STUDY FINDINGS OF PHASE II CLINICAL TRIAL OF KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" IN THE LANCET RESPIRATORY MEDICINE
2024-06-11
VOLUNTARY ANNOUNCEMENT - KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS
2024-06-11
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF POSITIVE CLINICAL DATA FROM PHASE 1 STUDY OF FS222 (CD137/PD-L1) AT THE 2024 ASCO
2024-06-05
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 5 JUNE 2024
2024-06-05
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2024-06-05
ADJUSTMENT TO CONVERSION PRICE OF THE BONDS
2024-06-05
RETIREMENT OF EXECUTIVE DIRECTOR
2024-06-05
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2024
2024-06-03
NEXT DAY DISCLOSURE RETURN
2024-05-17
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNOVATIVE DRUG BENMELSTOBART INJECTION "BENMELSTOBART (TQB2450)" IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE INDICATION OF FIRST-LINE TREATMENT FOR SMALL CELL LUNG CANCER
2024-05-09
IMPLEMENTATION OF SHARE INCENTIVE SCHEME BY CHIA TAI TIANQING
2024-05-07
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024
2024-05-06
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNVOATIVE DRUG UNECRITNIB FUMARATE CAPSULES "UNECRITINIB (TQ-B3101)"
2024-04-30
VOLUNTARY ANNOUNCEMENT - 52 RESEARCH RESULTS WILL BE PRESENTED AT 2024 ASCO ANNUAL MEETING
2024-04-29
NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS
2024-04-29
NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS
2024-04-29
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (OR ANY ADJOURNMENT THEREOF)
2024-04-29
GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING
2024-04-29
2023 ANNUAL REPORT
2024-04-29
VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "TQA3038 (siRNA)" COMPLETED PHASE I CLINICAL STUDY
2024-04-25
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
2024-04-19
NEXT DAY DISCLOSURE RETURN
2024-04-19
VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "ROVADICITINIB (TQ05105)" OBTAINED POSITIVE RESULTS IN KEY CLINICAL RESEARCH FOR REGISTRATION
2024-04-18
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
2024-04-17
NEXT DAY DISCLOSURE RETURN
2024-04-16
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
2024-04-15
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
2024-04-12
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE PHASE II CLINICAL STUDY DATA ON KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"
2024-04-10
VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES", "TQB2916 (CD40 AGONIST)" AND "FHND6091 (PROTEASOME INHIBITOR)" WERE PRESENTED AT 2024 AACR
2024-04-10
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
2024-04-08
English